Merck KGaA Acquires Bio-Techne for $73 Per Share in Cash
Merck KGaA has agreed to acquire Bio-Techne for $73 per share in cash, a deal valued at over $10 billion. Bio-Techne shares jumped more than 20% following the announcement. The acquisition is expected to close in the second half of 2026, pending regulatory approvals.
Key Numbers
On June 25, 2026, German pharmaceutical and life sciences giant Merck KGaA announced it will acquire Bio-Techne Corporation (NASDAQ: TECH) for $73 per share in cash. The offer represents a premium of more than 20% over Bio-Techne's closing price prior to the announcement and values the company at over $10 billion.
Deal Details
- Buyer: Merck KGaA
- Target: Bio-Techne (TECH)
- Price per share: $73 cash
- Total value: Over $10 billion (estimated)
- Premium: >20% over previous close
- Payment: All cash
- Expected close: Second half of 2026, subject to regulatory approvals
Rationale
Merck KGaA aims to strengthen its life sciences division, particularly in diagnostics and research tools. Bio-Techne's portfolio of recombinant proteins, antibodies, and assays complements Merck's existing offerings and expands its reach in the fast-growing life sciences market.
Regulatory Challenges
The deal will likely face antitrust reviews in the U.S. and Europe. Given the size and overlap, regulators may require certain divestitures or remedies. However, analysts expect approval given the competitive nature of the sector.
Impact on Stocks
Bio-Techne shares surged over 20% in today's trading, nearing the $73 offer price. Merck KGaA shares fell slightly by about 1.5%, typical for large acquisitions. For Danaher (DHR), the deal is not directly impactful but could increase competitive pressure in the life sciences tools space.
Frequently Asked Questions
Found this useful? Share it